psalexa
logo

Nasal Polyps Therapeutics Pipeline Analysis

Nasal Polyps Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11247
Available Format:

Nasal polyps are the type of lesions that arises from the mucosa of the nasal cavity. The cause of nasal polyps is still unknown. According to researchers, chronic inflammation in the nose and nasal sinuses are responsible for the occurrence of nasal polyps. Nasal polyps can be symptomatized by the runny nose, postnasal drip, absent sense of smell, facial pain, pain in upper teeth, snoring, persistent stuffiness, and sense of pressure over the forehead. The risk factors for nasal polyps include asthma, allergic fungal sinusitis, cystic fibrosis, chronic sinus infection, hay fever and aspirin sensitivity. The complication associated with nasal polyps are the infection (bacterial or viral), recurrent polyps and bleeding. Sanofi SA is in the process of developing SAR231893 as an interleukin 4 receptor type I antagonist for the treatment of nasal polyps. GlaxoSmithKline plc is in the process of developing mepolizumab as interleukin 5 inhibitor for the treatment of nasal polyps. Some of the companies having the pipeline of nasal polyps include Sanofi SA, Pfizer, Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry